CAT To Start Trials of Anti-TGF-Beta-2
Cambridge Antibody Technology has been granted approval in the UK tobegin clinical trials of its anti-transforming growth factor-beta-2 antibody in patients with early proliferative vitreous retinopathy.
The Phase I/IIa study will enroll up to 45 patients at three centers in the UK, and will try to determine the dose of antibody to be tested in future trials. It is given by intravitreal injection at the time of surgery. This is the second CAT antibody to enter trials, after studies of its antitumor necrosis factor alfa antibody were started in rheumatoid arthritis by partner Knoll earlier this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze